Glenmark Pharmaceuticals Limited Share Price & Analysis
₹2,165Updated 5 Jun 2026, 03:30 pm IST
LTP
₹2,165
—
Open
₹2,191.9
High
₹2,216.2
Low
₹2,161
Close
₹2,180.6
52W High
₹2,474
52W Low
₹1,473
Volume
513K
Lot Size
375
Sector
Healthcare
Market Cap
₹62K Cr
Face Value
₹1
Large CapNIFTY 200NIFTY 500MIDCAP 100
Price Chart
Fundamentals
P/E
20.9
Sector P/E
48.9
P/B
5.82
EPS
₹37.74
ROE
30.5%
ROCE
39.8%
D/E Ratio
0.06
Div Yield
0.11%
Book Value
₹372
+
Strengths
- ✓Excellent return on equity (ROE 30.5%)
- ✓Efficient capital deployment (ROCE 39.8%)
- ✓Attractively valued vs sector (P/E 20.9x vs industry 48.9x)
- ✓Virtually debt-free
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,783 | ₹4.3L Cr | 34.4 | 5.12 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,616 | ₹1.7L Cr | 66.1 | 10.48 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,416 | ₹1.5L Cr | 66.4 | 17.81 | 27.6 | 15.4 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,315 | ₹1.2L Cr | 59.5 | 12.62 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,402 | ₹1.1L Cr | 27.3 | 3.29 | 12.4 | 16.6 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,091 | ₹1.1L Cr | 20 | 4.05 | 21.2 | 21.2 | 0.38 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,283 | ₹1.1L Cr | 25.4 | 2.83 | 11.8 | 13.6 | 0.16 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
GLENMARK · as of Mar 2026
Promoters46.65%
FII23.15%▼0.36
DII14.60%▲0.75
Public15.56%▼0.40
Govt0.04%
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% |
| FII | 23.71% | 21.38% | 20.98% | 23.05% | 23.51% | 23.15% |
| DII | 10.92% | 13.36% | 13.93% | 13.21% | 13.85% | 14.60% |
| Public | 18.70% | 18.58% | 18.42% | 17.06% | 15.96% | 15.56% |
| Govt | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
Corporate Events
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend28 May 2026
Interim Dividend - Rs 2.50 Per Share
Dividend2 Oct 2025
Dividend - Rs 2.50 Per Share
Dividend14 Sept 2025
Dividend - Rs 2.50 Per Share
Dividend12 Sept 2024
Dividend - Rs 2.50 Per Share
Dividend17 Sept 2023
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.9K Cr ▼35.5% | ₹6.0K Cr ▲85.3% | ₹3.3K Cr ▲0.2% | ₹3.3K Cr ▼3.9% | ₹3.4K Cr ▼1.3% | ₹3.4K Cr ▲5.9% | ₹3.2K Cr ▲5.9% | ₹3.1K Cr |
| Op. Profit | ₹870 Cr ▼63.1% | ₹2.4K Cr ▲306.2% | ₹581 Cr ▲3.6% | ₹561 Cr ▼6.5% | ₹600 Cr ▼0.3% | ₹602 Cr ▲2.4% | ₹588 Cr ▲16.7% | ₹504 Cr |
| OPM | 22.0% ▼43.6% | 39.0% ▲116.7% | 18.0% ▲5.9% | 17.0% ▼5.6% | 18.0% ▲0.0% | 18.0% ▲0.0% | 18.0% ▲12.5% | 16.0% |
| Net Profit | ₹403 Cr ▼33.9% | ₹610 Cr ▲1197.9% | ₹47 Cr ▲1075.0% | ₹4 Cr ▼98.9% | ₹348 Cr ▼1.7% | ₹354 Cr ▲4.1% | ₹340 Cr ▲128.0% | ₹-1.2K Cr |
| EPS (₹) | 14.29 ▼33.9% | 21.63 ▲1203.0% | 1.66 ▲937.5% | 0.16 ▼98.7% | 12.33 ▼1.8% | 12.55 ▲4.1% | 12.06 ▲127.9% | -43.17 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹17.0K Cr ▲27.5% | ₹13.3K Cr ▲12.8% | ₹11.8K Cr ▲2.0% | ₹11.6K Cr ▼5.9% | ₹12.3K Cr ▲12.4% | ₹10.9K Cr ▲2.8% | ₹10.6K Cr ▲7.9% | ₹9.9K Cr ▲8.7% | ₹9.1K Cr ▼0.1% | ₹9.1K Cr |
| Expenses | ₹12.4K Cr ▲13.1% | ₹11.0K Cr ▲3.3% | ₹10.6K Cr ▲6.7% | ₹9.9K Cr ▼0.3% | ₹10.0K Cr ▲12.6% | ₹8.9K Cr ▼0.9% | ₹8.9K Cr ▲8.0% | ₹8.3K Cr ▲11.0% | ₹7.5K Cr ▲5.9% | ₹7.0K Cr |
| Op. Profit | ₹4.6K Cr ▲94.5% | ₹2.4K Cr ▲96.7% | ₹1.2K Cr ▼26.9% | ₹1.6K Cr ▼29.7% | ₹2.3K Cr ▲11.7% | ₹2.1K Cr ▲22.7% | ₹1.7K Cr ▲7.1% | ₹1.6K Cr ▼1.9% | ₹1.6K Cr ▼20.6% | ₹2.0K Cr |
| OPM | 27.0% ▲50.0% | 18.0% ▲80.0% | 10.0% ▼28.6% | 14.0% ▼26.3% | 19.0% ▲0.0% | 19.0% ▲18.8% | 16.0% ▲0.0% | 16.0% ▼11.1% | 18.0% ▼18.2% | 22.0% |
| Other Income | ₹-1.8K Cr ▼596.9% | ₹-259 Cr ▼177.1% | ₹336 Cr ▲3460.0% | ₹-10 Cr ▲90.1% | ₹-101 Cr ▼206.3% | ₹95 Cr ▼50.3% | ₹191 Cr ▼49.1% | ₹375 Cr ▲321.3% | ₹89 Cr ▲302.3% | ₹-44 Cr |
| Interest | ₹209 Cr ▲1.0% | ₹207 Cr ▼59.9% | ₹516 Cr ▲47.9% | ₹349 Cr ▲17.1% | ₹298 Cr ▼15.6% | ₹353 Cr ▼6.4% | ₹377 Cr ▲12.5% | ₹335 Cr ▲17.1% | ₹286 Cr ▲20.7% | ₹237 Cr |
| Depreciation | ₹573 Cr ▲17.9% | ₹486 Cr ▼16.5% | ₹582 Cr ▲2.3% | ₹569 Cr ▲16.8% | ₹487 Cr ▲9.7% | ₹444 Cr ▲6.5% | ₹417 Cr ▲27.9% | ₹326 Cr ▲7.9% | ₹302 Cr ▲14.4% | ₹264 Cr |
| PBT | ₹2.0K Cr ▲41.9% | ₹1.4K Cr ▲222.4% | ₹434 Cr ▼38.6% | ₹707 Cr ▼50.9% | ₹1.4K Cr ▲4.3% | ₹1.4K Cr ▲26.1% | ₹1.1K Cr ▼15.8% | ₹1.3K Cr ▲16.3% | ₹1.1K Cr ▼24.9% | ₹1.5K Cr |
| Tax % | 31.0% ▲24.0% | 25.0% ▼94.2% | 430.0% ▲814.9% | 47.0% ▲51.6% | 31.0% ▲3.3% | 30.0% ▲3.4% | 29.0% ▲0.0% | 29.0% ▲3.6% | 28.0% ▲7.7% | 26.0% |
| Net Profit | ₹1.4K Cr ▲30.1% | ₹1.0K Cr ▲173.0% | ₹-1.4K Cr ▼480.4% | ₹377 Cr ▼62.1% | ₹994 Cr ▲2.5% | ₹970 Cr ▲25.0% | ₹776 Cr ▼16.1% | ₹925 Cr ▲15.0% | ₹804 Cr ▼27.5% | ₹1.1K Cr |
| EPS (₹) | 48.26 ▲30.0% | 37.11 ▲169.7% | -53.22 ▼605.4% | 10.53 ▼68.4% | 33.37 ▼2.9% | 34.38 ▲25.0% | 27.5 ▼16.1% | 32.78 ▲15.1% | 28.49 ▼27.5% | 39.29 |
| Div Payout | 5.0% ▼28.6% | 7.0% ▲240.0% | -5.0% ▼120.8% | 24.0% ▲242.9% | 7.0% ▲0.0% | 7.0% ▼22.2% | 9.0% ▲50.0% | 6.0% ▼14.3% | 7.0% ▲40.0% | 5.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹28 Cr ▲0.0% | ₹28 Cr ▲0.0% | ₹28 Cr ▲0.0% | ₹28 Cr ▲0.0% | ₹28 Cr ▲0.0% | ₹28 Cr ▲0.0% | ₹28 Cr ▲0.0% | ₹28 Cr ▲0.0% | ₹28 Cr ▲0.0% | ₹28 Cr |
| Reserves | ₹9.6K Cr ▲8.3% | ₹8.8K Cr ▲12.8% | ₹7.8K Cr ▼17.2% | ₹9.4K Cr ▲4.3% | ₹9.1K Cr ▲28.7% | ₹7.0K Cr ▲16.5% | ₹6.0K Cr ▲8.3% | ₹5.6K Cr ▲8.6% | ₹5.1K Cr ▲15.0% | ₹4.5K Cr |
| Borrowings | ₹1.2K Cr ▼50.5% | ₹2.5K Cr ▲100.9% | ₹1.2K Cr ▼73.3% | ₹4.6K Cr ▲16.3% | ₹4.0K Cr ▼20.5% | ₹5.0K Cr ▲2.4% | ₹4.9K Cr ▲9.4% | ₹4.4K Cr ▼4.1% | ₹4.6K Cr ▼1.8% | ₹4.7K Cr |
| Other Liabilities | ₹8.2K Cr ▲75.5% | ₹4.7K Cr ▼11.6% | ₹5.3K Cr ▼0.2% | ₹5.3K Cr ▲32.1% | ₹4.0K Cr ▲13.6% | ₹3.5K Cr ▼5.5% | ₹3.7K Cr ▲15.3% | ₹3.2K Cr ▲15.8% | ₹2.8K Cr ▲9.6% | ₹2.5K Cr |
| Total Liabilities | ₹19.0K Cr ▲18.8% | ₹16.0K Cr ▲11.4% | ₹14.4K Cr ▼25.9% | ₹19.4K Cr ▲13.6% | ₹17.1K Cr ▲9.5% | ₹15.6K Cr ▲6.2% | ₹14.7K Cr ▲10.4% | ₹13.3K Cr ▲5.5% | ₹12.6K Cr ▲7.1% | ₹11.8K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹5.2K Cr ▲16.1% | ₹4.5K Cr ▲6.6% | ₹4.2K Cr ▼22.4% | ₹5.4K Cr ▼7.9% | ₹5.9K Cr ▲14.8% | ₹5.1K Cr ▲2.0% | ₹5.0K Cr ▲37.0% | ₹3.7K Cr ▲21.1% | ₹3.0K Cr ▲10.0% | ₹2.8K Cr |
| CWIP | ₹695 Cr ▼16.8% | ₹835 Cr ▲26.1% | ₹662 Cr ▼44.4% | ₹1.2K Cr ▲17.8% | ₹1.0K Cr ▼26.9% | ₹1.4K Cr ▲13.1% | ₹1.2K Cr ▼12.7% | ₹1.4K Cr ▲24.7% | ₹1.1K Cr ▲58.5% | ₹708 Cr |
| Investments | ₹42 Cr ▼25.0% | ₹56 Cr ▼92.9% | ₹790 Cr ▲1655.6% | ₹45 Cr ▼10.0% | ₹50 Cr ▲100.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▼16.7% | ₹30 Cr ▲100.0% | ₹15 Cr ▼6.3% | ₹16 Cr |
| Other Assets | ₹13.1K Cr ▲23.0% | ₹10.6K Cr ▲22.0% | ₹8.7K Cr ▼31.6% | ₹12.7K Cr ▲25.8% | ₹10.1K Cr ▲11.8% | ₹9.0K Cr ▲7.7% | ₹8.4K Cr ▲2.5% | ₹8.2K Cr ▼2.8% | ₹8.4K Cr ▲1.7% | ₹8.3K Cr |
| Total Assets | ₹19.0K Cr ▲18.8% | ₹16.0K Cr ▲11.4% | ₹14.4K Cr ▼25.9% | ₹19.4K Cr ▲13.6% | ₹17.1K Cr ▲9.5% | ₹15.6K Cr ▲6.2% | ₹14.7K Cr ▲10.4% | ₹13.3K Cr ▲5.5% | ₹12.6K Cr ▲7.1% | ₹11.8K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹-828 Cr ▼212.5% | ₹-265 Cr ▼142.4% | ₹625 Cr ▼43.6% | ₹1.1K Cr ▼1.9% | ₹1.1K Cr ▼18.8% | ₹1.4K Cr ▲5.1% | ₹1.3K Cr ▼19.7% | ₹1.6K Cr ▲150.8% | ₹657 Cr ▲90.4% | ₹345 Cr |
| Investing CF | ₹58 Cr ▼98.7% | ₹4.4K Cr ▲951.8% | ₹-515 Cr ▼63.0% | ₹-316 Cr ▲52.3% | ₹-662 Cr ▲14.5% | ₹-774 Cr ▲12.3% | ₹-883 Cr ▲12.0% | ₹-1.0K Cr ▼0.2% | ₹-1.0K Cr ▼5.4% | ₹-950 Cr |
| Financing CF | ₹787 Cr ▲120.1% | ₹-3.9K Cr ▼4972.7% | ₹-77 Cr ▲85.2% | ₹-520 Cr ▼17.6% | ₹-442 Cr ▲0.7% | ₹-445 Cr ▲39.8% | ₹-739 Cr ▼57.9% | ₹-468 Cr ▼186.2% | ₹543 Cr ▼22.3% | ₹699 Cr |
| Net Cash Flow | ₹17 Cr ▼92.1% | ₹215 Cr ▲571.9% | ₹32 Cr ▼88.2% | ₹272 Cr ▲871.4% | ₹28 Cr ▼83.9% | ₹174 Cr ▲158.6% | ₹-297 Cr ▼267.8% | ₹177 Cr ▼11.1% | ₹199 Cr ▲114.0% | ₹93 Cr |
| Free Cash Flow | ₹-1.6K Cr ▼35.5% | ₹-1.2K Cr ▼1649.3% | ₹75 Cr ▼76.6% | ₹320 Cr ▼29.8% | ₹456 Cr ▼26.0% | ₹616 Cr ▼13.5% | ₹712 Cr ▲13.9% | ₹625 Cr ▲922.4% | ₹-76 Cr ▲86.0% | ₹-544 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 92d ▲61.4% | 57d ▼50.4% | 115d ▲25.0% | 92d ▲7.0% | 86d ▲3.6% | 83d ▲2.5% | 81d ▼13.8% | 94d ▼3.1% | 97d ▼19.2% | 120d |
| Inventory Days | 254d ▲22.1% | 208d ▲2.5% | 203d ▼2.4% | 208d ▼9.6% | 230d ▲9.0% | 211d ▼13.5% | 244d ▲0.0% | 244d ▼18.4% | 299d ▲20.1% | 249d |
| Days Payable | 216d ▲2.9% | 210d ▲22.1% | 172d ▼9.5% | 190d ▼15.9% | 226d ▲7.6% | 210d ▼12.9% | 241d ▲7.1% | 225d ▼7.4% | 243d ▼21.1% | 308d |
| Cash Conv. Cycle | 129d ▲130.4% | 56d ▼61.9% | 147d ▲33.6% | 110d ▲22.2% | 90d ▲7.1% | 84d ▼1.2% | 85d ▼24.8% | 113d ▼25.7% | 152d ▲149.2% | 61d |
| Working Capital Days | 44d ▲2300.0% | -2d ▼101.4% | 141d ▲116.9% | 65d ▼3.0% | 67d ▲24.1% | 54d ▼15.6% | 64d ▼35.4% | 99d ▼20.8% | 125d ▲145.1% | 51d |
| ROCE | 19.0% ▲58.3% | 12.0% ▲20.0% | 10.0% ▼37.5% | 16.0% ▲6.7% | 15.0% ▲7.1% | 14.0% ▼6.7% | 15.0% ▲0.0% | 15.0% ▼28.6% | 21.0% ▲10.5% | 19.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Glenmark Pharmaceuticals Limited share price today?▾
Glenmark Pharmaceuticals Limited (GLENMARK) is currently trading at ₹2,165 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Glenmark Pharmaceuticals Limited available in F&O (Futures & Options)?▾
Yes, Glenmark Pharmaceuticals Limited (GLENMARK) is part of the NSE F&O segment with a lot size of 375 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Glenmark Pharmaceuticals Limited 52-week high and low?▾
Glenmark Pharmaceuticals Limited's 52-week high is ₹2,474 and the 52-week low is ₹1,473. The current price of ₹2,165 is 12.5% below the 52W high.
What is Glenmark Pharmaceuticals Limited P/E ratio?▾
Glenmark Pharmaceuticals Limited's current P/E ratio is 20.9. This indicates the market is paying ₹20.9 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Glenmark Pharmaceuticals Limited options?▾
Glenmark Pharmaceuticals Limited options are traded on NSE with monthly expiry contracts (lot size: 375 shares). To trade GLENMARK options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.